Tonix Pharmaceuticals to Present at Guggenheim’s 3rd Annual Healthcare Innovation Conference
Globe Newswire•04/11/2026•07:00 ET
0
Key Highlights
- ➤Tonix management to present at Guggenheim’s healthcare innovation conference November 10
- ➤Seth Lederman will present and host one-on-one investor meetings
- ➤TONMYA is approved for fibromyalgia and marketed by Tonix
- ➤Tonix markets Zembrace SymTouch and Tosymra acute migraine products
- ➤TNX-102 SL, TNX-4800, TNX-801 and TNX-1500 remain in development
BERKELEY HEIGHTS, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or “the Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced that management will present and host 1x1 meetings at Guggenheim’s 3rd Annual Healthcare Innovation Conference in Boston, Massachusetts on Tuesday, November 10, 2026.
Guggenheim’s 3rd Annual Healthcare Innovation Conference Company Presentation Presenter: Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals Date: Tuesday November 10, 2026 Presentation Time: 4:00-4:25 p.m. ET
Get started
Create a free account to read the full story.